• Biovica received a ninth work order from a leading global pharmaceutical customer for DiviTum TKa testing services.
• Order supports a breast cancer clinical study of a next-generation CDK inhibitor with endocrine therapy, featuring serial testing for up to four years.
• Work to run through Biovica’s CLIA-certified laboratory in San Diego, with testing expected to start in October 2026.
• Order value set at about SEK 1.7 million, covering sample testing, related laboratory services.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biovica International AB published the original content used to generate this news brief on July 14, 2026, and is solely responsible for the information contained therein.